anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a method for modulating CD200 receptors.  <P>SOLUTION: There is provided a method for modulating the activity of a cell. The method includes a process for bringing the cell into contact with a connection composition originated from the antigen-binding site of an antibody specifically binding to CD200Ra (the sequence number 2 or 6) or an antigenic fragment thereof. The cell is an obese cell. The modulation inhibits the activity of the cell or stimulates the activity of the cell. Or the modulation inhibits the activity of the cell, and the connection composition contains the agonist of CD200Ra (the sequence number 2 or 6), or the modulation increases the activity of the cell, and the connection composition contains the antagonist of CD200Ra (the sequence number 2 or 6).  <P>COPYRIGHT: (C)2011,JPO&INPIT
Chronic obstructive pulmonary disease (COPD), characterized by clinical sub-phenotypes such as emphysema (E) and chronic bronchitis (CB), is associated with a greater risk of lung cancer (LC). This study aimed to assess the expression patterns of circRNA and their potential functional involvement in LC patients with COPD. A circRNA microarray was used to characterize differentially expressed circRNAs (DEcircRNAs) profiles. A total of 176, 240, 163, and 243 DEcircRNAs were identified in comparisons between CB vs. LC patients (Con), E vs. Con, E vs. CB, and CBE vs. Con, respectively. DEcircRNAs in all comparison groups were primarily associated with immune-related GO terms and were also enriched in immune and inflammatory pathways. In total, 49 DEcircRNAs were significantly correlated with the infiltration of multiple immune cells. Among them, hsa-MROH9_0001 and hsa-RP11-35J10_0013 were positively and negatively correlated with plasma cells and T-cell CD4 memory resting cells, respectively; these two DEcircRNA-sponged miRNAs have good diagnostic performance. WGCNA identified six key circRNAs associated with CB progression. The expression patterns of hsa-MROH9_0001 and circRNA_21729 in E and CB groups were confirmed by RT-qPCR. In conclusion, we reported circRNA profiles and the findings demonstrated that hsa-MROH9_0001 and circRNA_21729 may be potential therapeutic targets for LC with COPD.
The participants will be told that their account has been credited a certain amount of money for the upcoming 30 days. However, for each day they do not meet their goal of at least 7000 steps, they will lose a small portion of that money. The participant will receive either an email or text message (based on the participant's preference) stating whether the participant achieved the goal for the prior day. Non-adherent participants will receive messages about how much the participant would have kept had they met the target step goal.
The invention provides a preparation method of a tribulus terrestris formula particle. In the extraction method of the alcohol-soluble extract, the caltrop decoction pieces are put into water with preset temperature according to preset proportion and soaked for preset time. So that the alcohol-soluble extract in the cells is dissolved in water. The concentration difference between the inside and the outside of the cell occurs, and larger osmotic pressure is generated, so that the alcohol soluble extract in the cell can smoothly permeate and diffuse into water outside the cell. When the water temperature is gradually increased during decoction, cells further absorb water to expand, and the alcohol soluble extract in the caltrop decoction pieces can be dissolved in water more quickly and completely. Therefore, the preparation method of the tribulus terrestris formula granule can improve the transfer rate of the alcohol-soluble extract, so that the content of the alcohol-soluble extract in the prepared dry paste powder is increased.
Identification of genes associated with nonsyndromic hearing loss is a crucial endeavor given the substantial number of individuals who remain without a diagnosis after even the most advanced genetic testing. PKHD1L1 was established as necessary for the formation of the cochlear hair-cell stereociliary coat and causes hearing loss in mice and zebrafish when mutated. We sought to determine if biallelic variants in PKHD1L1 also cause hearing loss in humans. Exome sequencing was performed on DNA of four families segregating autosomal recessive nonsyndromic sensorineural hearing loss. Compound heterozygous p.[(Gly129Ser)];p.[(Gly1314Val)] and p.[(Gly605Arg)];p[(Leu2818TyrfsTer5)], homozygous missense p.(His2479Gln) and nonsense p.(Arg3381Ter) variants were identified in PKHD1L1 that were predicted to be damaging using in silico pathogenicity prediction methods. In vitro functional analysis of two missense variants was performed using purified recombinant PKHD1L1 protein fragments. We then evaluated protein thermodynamic stability with and without the missense variants found in one of the families and performed a minigene splicing assay for another variant. In silico molecular modeling using AlphaFold2 and protein sequence alignment analysis were carried out to further explore potential variant effects on structure. In vitro functional assessment indicated that both engineered PKHD1L1 p.(Gly129Ser) and p.(Gly1314Val) mutant constructs significantly reduced the folding and structural stabilities of the expressed protein fragments, providing further evidence to support pathogenicity of these variants. Minigene assay of the c.1813G>A p.(Gly605Arg) variant, located at the boundary of exon 17, revealed exon skipping leading to an in-frame deletion of 48 amino acids. In silico molecular modeling exposed key structural features that might suggest PKHD1L1 protein destabilization. Multiple lines of evidence collectively associate PKHD1L1 with nonsyndromic mild-moderate to severe sensorineural hearing loss. PKHD1L1 testing in individuals with mild-moderate hearing loss may identify further affected families.
The invention relates to a traditional Chinese medicine for curing children cough which is characterized in that the traditional Chinese medical materials used for preparing the medicine is 12-17g of dense moxibustion cortex mori radicis, 5-10g of fring bitter almond, 15-20g of radix peucedani, 10-15g of arctium, 10-15g of balloon flower, 10-12g of liquorice. The preparation method of the medicine is that: the medicines are taken; added with water to extract for there times; added with twelve times water in the first time, marinated for half hour, decocted for one and a half hours; added with ten times water in the second time, decocted for one and a half hours; added with ten times water in the third time, decocted for one and a half hours. The decoction is combined and filtered, and the filtrate is concentrated to 800ml and filtered. The filtrate is added with ethanol to cause that the content to reach 70 percent, then is stirred and stewed for 12 hours, filtered again. The filtrate decompresses to recover ethanol. The liquid medicine is added with water to 800 ml, evenly stirred, stewed for 12 hours, filtered, added with 100g of sugar, 1g of citric acid, 2g of sodium benzoate, 0.5ml of flavour composition, stirred to dissolve, added with distilled water to adjust the gross to 1000ml, filtered, encapsulated (10ml/one), sterilized, then the medicine is obtained. The medicine has obvious efficacy of relieving cough, eliminating phlegm, relieving asthma, and can effectively improve the clinical symptom of children.
The invention discloses dopexamine hydrochloride injection. The dopexamine hydrochloride injection is composed of dopexamine hydrochloride, a complexing agent and a solvent. The formed injection has a specific pH value, and subpackaged into each ampoule bottle. A preparation method of the dopexamine hydrochloride injection comprises the following steps: in the water for injection with the 70% total volume, adding dopexamine hydrochloride and arginine with the prescription amount, stirring for dissolving, adding water for injection for making constant volume till reaching the total volume; adding with activated carbon with the volume accounting for 0.2% of the total volume, stirring for 15 min, and filtering by a filter membrane of 0.22 mu m; and taking 5mL of the obtained mixed liquid, canning into a 5mL ampoule bottle, charging nitrogen and carrying out heat sealing, and sterilizing at 121 DEG C for 15 min. According to the dopexamine hydrochloride injection and the preparation method thereof, the prescription is simple, the pH is 5-7, the injection is stable after compatibility of medicines, the content can not decline, the injection is particularly suitable for the clinic, wherein arginine is the human endogenous substance, the use amount of arginine is reasonable, and therefore, the safety is high. The use amount of the arginine is safe.
1317941 Amino-benzoic acid derivatives LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB 2 June 1971 [18 June 1970] 29740/70 Heading C2C Novel compounds of the general Formula I wherein R 1 is a straight or branched, saturated or unsaturated C 3-8 alkyl radical which is optionally substituted with C 1-4 alkoxy or alkylthio; a mononuclear-aromatically substituted methyl or ethyl radical or a mononuclearheterocyclically substituted methyl or ethyl radical; A is a phenoxy, phenylthio, benzoyl, benzyl or α-hydroxybenzyl radical which is optionally substituted with one or more chlorine or bromine atom or C 1-4 alkyl, halo-C 1-4 alkyl, carboxy, carbalkoxy, carbamyl or di-C 1-4 -alkyl amino radicals, or hydroxy groups which may be etherified or esterified or etherified mercapto groups; R 2 is hydrogen, C 1-4 alkyl or alkoxy or unsubstituted or mono- or di-C 1-4 alkyl substituted amino and pharmaceutically acceptable salts thereof may be prepared by reacting a compound II: with an acid R 2 COOH or a reactive derivative thereof or with a carbamyl halide or an alkyl isocyanate or isocyanic acid or an alkyl chloroformate. The intermediate II may be formed by reduction of nitro to amino or in the case where A is benzyl or α-hydroxybenzyl, reduction of compounds in which A is benzoyl. The 3-nitro-benzoic acid precursors of II may be prepared by (a) N-alkyl or aralkylation to form the NHR 1 group followed by hydrolysis of the salt or ester of the intermediate to form the free carboxylic acid group. 3 - Amino - 5 - nitro - 4 - phenoxyl benzoic acid is produced by forming the pyridinium salt of 3,5 - dinitro - 4 - phenoxyl benzoic acid and selectively reducing one of the nitro groups. 3 - Amino - 5 - nitro - 4 - phenylthiobenzoic acid is formed from 4-chloro-3,5-dinitro benzoic acid by reaction with thiophenol to produce 3,5- dinitro-4-phenylthio benzoic acid followed by selective reduction of one nitro group. 3 - Amino - 4 - benzoyl - 5 - nitro - benzoic acid is formed from 4-carbethoxy-2,6-dinitro-benzoic acid by forming the acid chloride thereof and reacting this in a Friedel-Craft reaction with benzene to form ethyl-4-benzoyl-3,5-dinitrobenzoic acid which is converted to the free acid and the 3-nitro group selectively reduced. 2 - Benzylamino - 5 - nitro - 4 - phenoxybenzoic acid is formed from 4-chloro-2-fluorobenzoic acid by nitration to yield 4-chloro-2- fluoro-5-nitro-benzoic acid then reaction with benzyl amine to yield 2-benzylamino-4-chloro- 5-nitro-benzoic acid followed by treatment with sodium phenolate to yield sodium 2-benzylamino - 5 - nitro - 4 - phenoxy - benzoate followed by hydrolysis to the free acid. Pharmaceutical compositions of the compounds I show diuretic and saluretic activity when administered orally or parenterally with the usual excipients.
[GB1317941A]
COVID-19 represents an acute crisis to children's mental health, with potential for long-term consequences. There is evidence for elevated mental health symptomatology in children since the start of the pandemic, with the emergence of stress-related disorders and the exacerbation of pre-existing disorders. Indeed, the pandemic has had detrimental effects on family life due to widespread job loss and financial insecurity, and increases to parental psychological distress, mental illness, and substance use. Social consequences of COVID-19 are expected to have cascading negative effects on child mental health symptoms. Thus, a COVID-19 family recovery program is critically needed, both during and after the pandemic, to manage the current mental health crisis in children and create cascading and sustainable effects for lifelong physical and mental health. The main goal of the the current study is to investigate feasibility of a future pilot and/or main RCT of a brief, virtual mental health treatment program for children and families designed to optimize reach of services. Specifically, the Lausanne Trialogue Play paradigm assessment is a semi-structured assessment of whole family interactions, with emphasis on the co-parenting relationship, which has been used extensively in research settings for assessment and consultative purposes. The current study will assess the feasibility of using the LTP in an assessment-as-treatment model. This brief treatment program, called the LTP-Brief intervention (LTP-B) will consist of a family play assessment (including an LTP assessment) with video feedback to caregivers as a method for promoting change in family interaction patterns. By targeting change across the family system, rather than focusing on specific child mental health symptoms directly, the model addresses upheaval of family life during COVID-19 and has potential to create sustainable improvements in family well-being within a short period of time.
BACKGROUND: Foetal reduction, which involves selectively terminating one or more foetuses in a multiple gestation pregnancy, has become more common. This systematic review and meta-analysis aims to assess and compare pregnancy outcomes of foetal reduction from twin to singleton gestation to ongoing twin gestations.
METHODS: A comprehensive search of electronic databases (MEDLINE, EMbase, Cochrane Library, CINAHL and PsycINFO) was done for studies published until 15 April 2023. The outcomes analysed included gestational diabetes mellitus (DM), hypertension, caesarean delivery, foetal loss, perinatal death, preterm birth (PTB), intrauterine growth restriction (IUGR), preterm prelabour rupture of membranes (PPROM) and birth weight.
RESULTS: A total of 13 studies comprising 1241 cases of twin to singleton foetal reduction gestation were compared to 20,693 ongoing twin gestations. Our findings indicate that foetal reduction was associated with a significantly lower risk of developing maternal gestational DM (odds ratio [OR] = 0.40, 95% confidence interval [CI] 0.27-0.59) and hypertension (OR = 0.36, 95% CI 0.23-0.57) compared to the control group. Incidence rate of caesarean delivery (OR = 0.65, 95% CI 0.53-0.81) after foetal reduction was significantly lower compared to ongoing twin gestations. There was a 63% lower chance of PTB before 37 weeks of pregnancy. However, there was no significant association between foetal reduction and outcomes such as foetal loss, perinatal death, IUGR and PPROM.
CONCLUSIONS: Our findings suggest that foetal twin to singleton reduction entails potential benefits as compared to ongoing twin gestations. Further well planned studies are needed to explore underlying mechanisms to understanding of the outcomes associated with foetal reduction procedures and inform clinical decision-making for pregnant individuals and healthcare providers alike.
Mechanical ventilatory strategy of the ARDS Network low PEEP-FiO2 table will be followed in the control arm. This strategy consists of at least 12 hours of controlled mechanical ventilation following prespecified PEEP and FiO2 combinations chosen dynamically targeting oxygenation. Tidal volume is set at 4-6 mL/Kg of predicted body weight (PBW) and plateau pressure is kept below 30 centimeters of water (cmH2O). Respiratory rate can be as high as 35 breaths per minute titrated to a potential of hydrogen (pH) 7.30-7.45. As oxygenation improves, patients are transitioned to assisted ventilation and then to pressure support ventilation until they are ready to be liberated from the ventilator. During this phase, no attempt is made to control plateau pressures or tidal volumes. In the intervention arm, minimizing tidal lung strain by keeping driving pressure below 16 cmH2O throughout the mechanical ventilation period will be targeted. The controlled phase will last at least 48 hours. PEEP will be selected according to a PEEP titration maneuver with EIT at the start of the intervention. This PEEP level will be kept until extubation. Respiratory rate can be as high as 50 breaths per minute targeting a pH of 7.15-7.45.
The anti-carcinogen injection made by the process of the present invention is suitable for treating and preventing various kinds of malignant tumors such as liver cancer, lung cancer, thyroid cancer, prostatic cancer, rectum cancer, etc. and is especially suitable for treating the liver cancer and the lung cancer; the inhibition ratio of various kinds of malignant tumors reaches 67%. The injection uses alive hagworm as a main raw material; six kinds of Chinese herbal medicine such as rhizoma corydalis, etc. are added; the injection is prepared through fine processing; the main technological processes comprise material selection, abdomen dissection, interception, washing, decoction, cooling to obtain clear liquid, deposition, filtration, package, etc. Animal experiments demonstrate that the injection has good prevention and treatment effect on the mouse ehrlich's ascites carcinoma and the liver cancer. The present invention is anti-carcinogen injection without toxicity or side effect.
This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the study intervention (HST003). HST003 will be injected into the microfracture defects (interstices) and fill the remainder of the defect to the cartilage margin following surgery.
PET/CT imaging of three patients using 68Ga-NY104 for medical reasons will be performed. Patients received an intravenous injection of 68Ga-NY104. Images will be obtained at 0.5 h, 1 h, and 2 h after injection. A comparative 18F-FDG PET/CT scan will also be performed if necessary. The study will be carried out on a time-of-flight PET/CT scanner. SUVmax and SUVmean of normal organs and lesions, as well as tumor-to-background ratios, will be quantitatively assessed using a region-of-interest technique.
BACKGROUND: Patient-reported outcome and experience measures can play a critical role in providing patient-centered and value-based health care to a growing population of patients who are chronically ill. Value-based telemedicine platforms such as the Naveta initiative may facilitate the effective integration of these tools into health care systems.
OBJECTIVE: This study aims to evaluate the response rate to electronic patient-reported outcome measures (ePROMs) and electronic patient-reported experience measures (ePREMs) among patients participating in the Naveta telemedicine initiative and its correlations with sociodemographic and clinical characteristics, as well as the evolution of the response rates over time.
METHODS: Between January 1, 2021, and June 30, 2023, a total of 53,364 ePREMs and ePROMs for 20 chronic conditions were administered through the Naveta-Phemium platform. Descriptive statistics were used to summarize continuous and categorical variables. Differences in response rates within each sociodemographic variable were analyzed using logistic regression models, with significance assessed via chi-square and post hoc Tukey tests. Two-way ANOVA was used to examine the interaction between time interval and disease type on response rate evolution.
RESULTS: A total of 3372 patients with severe chronic diseases from 64 public hospitals in Spain participated in the Naveta health questionnaire project. The overall response rate to ePROMs and ePREMs during the first 2.5 years of the Naveta initiative was 46.12% (24,704/53,364), with a baseline rate of 53.33% (7198/13,496). Several sociodemographic factors correlated with lower response rates, including male gender, older age, lower education level, frequent alcohol use, being a student, and not being physically active. There were also significant variations in response rates among different types of chronic conditions (P<.001), with the highest rates being for respiratory (433/606, 71.5%), oncologic (200/319, 62.7%), digestive (2247/3601, 62.4%), and rheumatic diseases (7506/12,982, 57.82%) and the lowest being for HIV infection (7473/22,695, 32.93%). During the first 6 months of follow-up, the response rates decreased in all disease types, except in the case of the group of patients with oncologic disease, among whom the response rate increased up to 100% (6/6). Subsequently, the overall response rate approached baseline levels.
CONCLUSIONS: Recognizing the influence of sociodemographic factors on response rates is critical to identifying barriers to participation in telemonitoring programs and ensuring inclusiveness in patient-centered health care practices. The observed decline in response rates at follow-up may be due to survey fatigue, highlighting the need for strategies to mitigate this effect. In addition, the variation in response rates across chronic conditions emphasizes the importance of tailoring telemonitoring approaches to specific patient populations.
Eligible breast cancer patients will receive hypofractionated radiotherapy of 2.67 Gy for 16 fractions (and sequential tumor bed boost of 2.67 Gy for 4 fractions in patients with intact breast) to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) at the discrection of radition oncologists. CTV including breast/chest wall and regional nodes will be contoured according to RTOG contouring atlas. Integrated multi-beam IMRT plan will be generated and optimized using our predefined protocol for OAR constrains and target coverage. All integrated IMRT plans will be designed using the Eclipse™ Treatment Planning System. All these tight margin IMRT plan will be passed in pre-treatment dry run with the motion management workflow involved and the target coverage during the treatment will be confirmed. The plans which pass the above on-line verification will then be de-identified and transferred to RapidPlan configuration workspace for RNI model training and verification.All enrolled patients will be regularly followed up during and after RT. Acute and late toxicity will be documented as well as tumor control endpoints.
The NFIX gene encodes a DNA-binding protein belonging to the nuclear factor one (NFI) family of transcription factors. Pathogenic variants of NFIX are associated with two autosomal dominant Mendelian disorders, Malan syndrome (MIM 614753) and Marshall-Smith syndrome (MIM 602535), which are clinically distinct due to different disease-causing mechanisms. NFIX variants associated with Malan syndrome are missense variants mostly located in exon 2 encoding the N-terminal DNA binding and dimerization domain or are protein-truncating variants that trigger nonsense-mediated mRNA decay (NMD) resulting in NFIX haploinsufficiency. NFIX variants associated with Marshall-Smith syndrome are protein-truncating and are clustered between exons 6 and 10, including a recurrent Alu-mediated deletion of exons 6 and 7, which can escape NMD. The more severe phenotype of Marshall-Smith syndrome is likely due to a dominant-negative effect of these protein-truncating variants that escape NMD. Here, we report a child with clinical features of Malan syndrome who has a de novo NFIX intragenic duplication. Using genome sequencing, exon-level microarray analysis, and RNA sequencing, we show that this duplication encompasses exons 6 and 7 and leads to NFIX haploinsufficiency. To our knowledge, this is the first reported case of Malan Syndrome caused by an intragenic NFIX duplication.